An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.
复制标题

整合的癌症基因组图谱(TCGA)泛癌临床数据资源助力高质量生存结局分析 。

DOI:
10.1016/j.cell.2018.02.052
复制
发表时间:
2018-04-05
期刊:
影响因子:
64.5
通讯作者:
Hu H
Hu H
中科院分区:
生物学1区
文献类型:
--
作者:
Liu J;Lichtenberg T;Hoadley KA;Poisson LM;Lazar AJ;Cherniack AD;Kovatich AJ;Benz CC;Levine DA;Lee AV;Omberg L;Wolf DM;Shriver CD;Thorsson V;Cancer Genome Atlas Research Network;Hu H

文献摘要

参考文献

被引文献

相似文献

十年来,癌症基因组图谱(TCGA)计划收集了33种不同癌症类型的11,000多个人类肿瘤的临床病理注释数据以及多平台分子图谱。TCGA临床数据包含代表数据收集过程民主化性质的关键特征。为了确保正确使用这个与基因组特征相关的大型临床数据集,我们开发了一个名为TCGA泛癌临床数据资源(TCGA-CDR)的标准化数据集,其中包括四个主要的临床结果终点。除了详细描述在整合已获得的临床数据的过程中遇到的主要挑战和统计限制外,我们还提供了一份摘要,其中包括针对每种癌症类型的终点使用建议。这些TCGA-CDR发现似乎与独立于TCGA努力的癌症基因组学研究一致,并为以前所未有的规模利用临床相关性研究癌症生物学提供了机会。简而言之,对TCGA计划中超过11,000名癌症患者的临床病理注释的分析导致了TCGA临床数据资源的生成,该资源为33种癌症提供了临床结果终点使用的建议。
For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data along with multi-platform molecular profiles of more than 11,000 human tumors across 33 different cancer types. TCGA clinical data contain key features representing the democratized nature of the data collection process. To ensure proper use of this large clinical dataset associated with genomic features, we developed a standardized dataset named the TCGA Pan-Cancer Clinical Data Resource (TCGA-CDR), which includes four major clinical outcome endpoints. In addition to detailing major challenges and statistical limitations encountered during the effort of integrating the acquired clinical data, we present a summary that includes endpoint usage recommendations for each cancer type. These TCGA-CDR findings appear to be consistent with cancer genomics studies independent of the TCGA effort and provide opportunities for investigating cancer biology using clinical correlates at an unprecedented scale. In Brief Analysis of clinicopathologic annotations for over 11,000 cancer patients in the TCGA program leads to the generation of TCGA Clinical Data Resource, which provides recommendations of clinical outcome endpoint usage for 33 cancer types.
DOI: 10.1038/nature12113
发表时间: 2013-05-02
期刊: Nature
影响因子: 64.8
作者:
通讯作者: --
DOI: 10.1016/j.cell.2015.10.025
发表时间: 2015-11-05
期刊: Cell
影响因子: 64.5
作者:
Cancer Genome Atlas Research Network
通讯作者: Cancer Genome Atlas Research Network
DOI: 10.1038/sj.bjc.6602678
发表时间: 2005-08-22
影响因子: 8.8
作者:
通讯作者: --
DOI: 10.1016/j.cell.2014.06.049
发表时间: 2014-08-14
期刊: Cell
影响因子: 64.5
作者:
Hoadley KA;Yau C;Wolf DM;Cherniack AD;Tamborero D;Ng S;Leiserson MDM;Niu B;McLellan MD;Uzunangelov V;Zhang J;Kandoth C;Akbani R;Shen H;Omberg L;Chu A;Margolin AA;Van't Veer LJ;Lopez-Bigas N;Laird PW;Raphael BJ;Ding L;Robertson AG;Byers LA;Mills GB;Weinstein JN;Van Waes C;Chen Z;Collisson EA;Cancer Genome Atlas Research Network;Benz CC;Perou CM;Stuart JM
通讯作者: Stuart JM
DOI: 10.1001/jamaoncol.2017.0595
发表时间: 2017-12-01
期刊: JAMA oncology
影响因子: 28.4
作者:
Huo D;Hu H;Rhie SK;Gamazon ER;Cherniack AD;Liu J;Yoshimatsu TF;Pitt JJ;Hoadley KA;Troester M;Ru Y;Lichtenberg T;Sturtz LA;Shelley CS;Benz CC;Mills GB;Laird PW;Shriver CD;Perou CM;Olopade OI
通讯作者: Olopade OI